drugset
drugset / Trial / NCT05738681

Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial

NCT05738681 ↗

Phase 2/3 Unknown 82 enrolled Mahidol University
RandomizedParallel-groupOpen-labelPrevention

Summary

To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).

Timeline

Start
2022-09-09
Primary completion
2023-03-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 1200 mg —

Indications

drug-induced liver injury hepatitis tuberculosis